Patents by Inventor Shaonan WANG

Shaonan WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYSTEMS AND METHODS FOR GENERAL-PURPOSE OUT-OF-CORE RANDOM WALK GRAPH COMPUTING
    Publication number: 20240078260
    Abstract: Systems and methods are provided for performing random walk graph computing. One method may comprise generating a subset of walkers on a graph, maintaining the generated subset of walkers in a walker pool in a memory, loading a coarse-grained block of the graph from a non-volatile storage into a block buffer of the memory, generating pre-sampled edges for vertices in the coarse-grained block, storing the pre-sampled edges into a pre-sampled edge buffer allocated for the coarse-grained block and moving one or more walkers of the generated subset of walkers using the pre-sampled edges stored in the pre-sampled edge buffer. The generated subset of walkers may have an initial number determined based on a memory space allocated to the walker pool.
    Type: Application
    Filed: September 2, 2022
    Publication date: March 7, 2024
    Inventors: Kang Chen, Yongwei Wu, Jinlei Jiang, Shuke Wang, Shaonan Ma, Ke Yang, Mingxing Zhang
  • DOSING REGIMEN OF AVELUMAB FOR THE TREATMENT OF CANCER
    Publication number: 20220220205
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Application
    Filed: February 9, 2022
    Publication date: July 14, 2022
    Inventors: Glen Ian Andrews, Carlo Leonel BELLO, Satjit Singh BRAR, Shaonan WANG, Pascal GIRARD
  • TITRATION OF CEBRANOPADOL
    Publication number: 20220110914
    Abstract: The invention relates to Cebranopadol for use in the treatment of pain, wherein Cebranopadol is administered according to an administration regimen comprising (i) a first administration interval, which lasts for at least 2 consecutive days, wherein a first daily dose of Cebranopadol is administered on every day of the first administration interval; and (ii) a second administration interval, which lasts for at least 2 consecutive days and directly follows the first administration interval without interruption, wherein a second daily dose of Cebranopadol is administered on every day of the second administration interval; wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Applicant: PARK THERAPEUTICS, INC.
    Inventors: Shaonan WANG, Chiara PIANA, Roberta BURSI
  • Dosing regimen of avelumab for the treatment of cancer
    Patent number: 11274154
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 15, 2022
    Assignees: PFIZER INC., MERCK PATENT GMBH
    Inventors: Glen Ian Andrews, Carlo Leonel Bello, Satjit Singh Brar, Shaonan Wang, Pascal Girard
  • Titration of Cebranopadol
    Patent number: 11229625
    Abstract: The invention relates to Cebranopadol for use in the treatment of pain, wherein Cebranopadol is administered according to an administration regimen comprising (i) a first administration interval, which lasts for at least 2 consecutive days, wherein a first daily dose of Cebranopadol is administered on every day of the first administration interval; and (ii) a second administration interval, which lasts for at least 2 consecutive days and directly follows the first administration interval without interruption, wherein a second daily dose of Cebranopadol is administered on every day of the second administration interval; wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: January 25, 2022
    Assignee: PARK THERAPEUTICS, INC.
    Inventors: Shaonan Wang, Chiara Piana, Roberta Bursi
  • Dosing Regimen of Avelumab for the Treatment of Cancer
    Publication number: 20190330352
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Application
    Filed: October 5, 2017
    Publication date: October 31, 2019
    Applicants: PFIZER INC, MERCK PATENT GmbH
    Inventors: Glen Ian Andrews, Carlo Leonel BELLO, Satjit Singh BRAR, Shaonan WANG, Pascal GIRARD
  • TITRATION OF CEBRANOPADOL
    Publication number: 20180369199
    Abstract: The invention relates to Cebranopadol for use in the treatment of pain, wherein Cebranopadol is administered according to an administration regimen comprising (i) a first administration interval, which lasts for at least 2 consecutive days, wherein a first daily dose of Cebranopadol is administered on every day of the first administration interval; and (ii) a second administration interval, which lasts for at least 2 consecutive days and directly follows the first administration interval without interruption, wherein a second daily dose of Cebranopadol is administered on every day of the second administration interval; wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol.
    Type: Application
    Filed: August 29, 2018
    Publication date: December 27, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: Shaonan WANG, Chiara PIANA, Roberta BURSI